Table 1 Patient characteristics and clinical outcomes according to the two cohorts
N. Pts | Age (years) | Sex | ECOG PS | Primary site | DFI (months) | Basal LDH | N. cycle of chemotherapy | Disease sites | Response (duration) | Survival (months) |
|---|---|---|---|---|---|---|---|---|---|---|
Cohort A | ||||||||||
1 | 69 | F | 1 | Skin | 4 | 360 | 7 | Lung Soft tissue Lymph nodes | PR (9 months) | 19+ |
2 | 76 | M | 1 | Skin | 2 | 238 | 6 | Soft tissue | PR (7 months) | 17+ |
3 | 49 | M | 1 | Unknown | _ | 324 | 2 | Lung Bowel | PR (6 months) CR (2 months) | 14 |
4 | 73 | M | 2 | Skin | 96 | 379 | 1 | Lung Brain | SD (4 months) | 4 |
5 | 62 | F | 1 | Anal mucosa | 11 | 403 | 7 | Endopelvic mass Lymph nodes | PD | 9 |
6 | 71 | M | 1 | Skin | 36 | 291 | 6 | Soft tissue Lymph nodes Bone | SD (5 months) | 14 |
7 | 64 | M | 1 | Scalp | 7 | 251 | 2 | Lung Bone | PD | 13+ |
Cohort B | ||||||||||
1 | 64 | M | 1 | Skin | 10 | 474 | 3 | Liver Lymph nodes Spleen Lung | PD | 5 |
2 | 38 | F | 2 | Skin | 11 | 309 | 7 | Soft tissue Adrenal gland Bone | PR (6 months) | 10 |
3 | 76 | F | 1 | Skin | 25 | 289 | 7 | Soft tissue Lymph nodes | SD (5 months) | 12 |
4 | 48 | F | 1 | Skin | 24 | 394 | 6 | Lung | SD (7 months) | 14+ |
5 | 42 | M | 0 | Skin | 12 | 442 | 3 | Liver Lung | PD | 13+ |
6 | 75 | F | 1 | Skin | 12 | 839 | 8 | Soft tissue Lymph nodes Liver | RP (11+ months) | 13+ |
7 | 59 | M | 0 | Skin | 24 | 330 | 6 | Lung Lymph nodes | SD (4 months) | 13+ |